Home / Publication / Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Author(s):

Year:

Recommended for you

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Webinar

Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

Webinar

Extrapolating AUC to Infinity

Blog

Calculating AUC (Linear and Log-linear)

Blog

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

Extrapolating AUC to Infinity

Calculating AUC (Linear and Log-linear)

Newsletter sign up

Quick links

Solutions

Contact